德國(guó)研究人員最新研發(fā)出一種新的基因檢測(cè)方法,，能夠提前判斷“抗腫瘤壞死因子療法”對(duì)患者的療效,，從而避免不適用這種療法的類風(fēng)濕性關(guān)節(jié)炎患者受到該療法副作用的影響。
德國(guó)沙里泰大學(xué)醫(yī)院27日發(fā)表公報(bào)說(shuō),，一種名叫腫瘤壞死因子的蛋白質(zhì)會(huì)導(dǎo)致類風(fēng)濕性關(guān)節(jié)炎等疾病,，“抗腫瘤壞死因子療法”通過(guò)阻斷這種蛋白質(zhì)來(lái)消除炎癥，但這種療法卻不適用于所有患者,，而且有一定副作用,。
該院研究人員利用逆轉(zhuǎn)錄聚合酶鏈反應(yīng)（RT－PCR）技術(shù)研究了27名類風(fēng)濕性關(guān)節(jié)炎患者的血液，發(fā)現(xiàn)患者體內(nèi)一種名為CD11c的基因表達(dá)強(qiáng)度與“抗腫瘤壞死因子療法”的療效有顯著關(guān)系,。
研究顯示,，這種療法只在CD11c基因表達(dá)較強(qiáng)的患者身上有效，而這類患者約占所有病例的60％,。
研究人員說(shuō),，利用新的基因檢測(cè)法，醫(yī)生可以提前確定“抗腫瘤壞死因子療法”是否適合某一患者,，避免了不適合此療法的患者受其副作用影響,。研究人員下一步希望將這種檢測(cè)方法與其他療法結(jié)合，開(kāi)發(fā)出更有效的新療法,。
這一成果發(fā)表在最新一期美國(guó)《臨床藥理學(xué)與治療學(xué)》雙月刊上,。(生物谷Bioon.com)
生物谷推薦原文出處：
Clinical Pharmacology & Therapeutics doi:10.1038/clpt.2009.244
CD11c as a Transcriptional Biomarker to Predict Response to Anti-TNF Monotherapy With Adalimumab in Patients With Rheumatoid Arthritis
B Stuhlmüller, T H?upl, M M Hernandez, A Grützkau, R-J Kuban, N Tandon, J W Voss, J Salfeld, R W Kinne and G R Burmester
We performed transcription profiling using monocytes to identify predictive markers of response to anti–tumor necrosis factor (anti-TNF) therapy in patients with rheumatoid arthritis (RA). Several potential predictors of response were identified, including CD11c. Validation in samples from independent cohorts (total of n = 27 patients) using reverse transcription–PCR confirmed increased expression of CD11c in responders to adalimumab (100% sensitivity; 91.7% specificity, power 99.6%; α = 0.01). Pretherapy CD11c levels significantly correlated with the response criteria as defined by the American College of Rheumatology (ACR) (r = 0.656, P < 0.0001). However, CD11c was neither predictive of response to methotrexate (MTX) alone (n = 34) nor to MTX in combination with adalimumab (n = 16). Clinical responders revealed a reset to a normal expression pattern of resident/inflammatory monocyte markers, which was absent in nonresponders. Therefore, an analysis of key cell types identifies potentially predictive biomarkers that may help to restrict the use of adalimumab to therapy responders. Larger studies, including studies of monotherapy with other drugs, are now needed to confirm and validate the specificity of CD11c for anti-TNF biologics.
